98%
921
2 minutes
20
Pregnant people are ubiquitously exposed to endocrine-disrupting phthalates through consumer products and food. The placenta may be particularly vulnerable to the adverse effects of phthalates, with evidence from animal models suggesting impacts on placental development and vascularization. We translate this research to humans, examining gestational exposure to phthalates and phthalate replacements in relation to novel markers of chorionic plate surface vascularization. Phthalate and phthalate replacement metabolites were measured in first trimester urine from pregnant participants in the Understanding Pregnancy Signals and Infant Development (UPSIDE) cohort (n = 154). At delivery, placentae underwent specialized 2D and 3D digital imaging to quantify chorionic plate surface vasculature. Using weighted quantile g-computation mixtures methods as well as multivariable linear regression models examining individual metabolites, we evaluated associations with overall chorionic plate surface area and five chorionic plate surface vascular measures, adjusting for covariates. We additionally examined interactions with placental sex. Exposure to a phthalate mixture was associated with longer total arterial arc length (β = 9.64 cm; 95%CI: 1.68, 17.59), shorter mean arterial arc length (β = -0.07 cm; 95%CI: -0.14, -0.01), and more arterial branch points (β = 5.77; 95%CI: 1.56, 9.98), but not chorionic plate surface area. In models considering individual metabolites and their molar sums, results were strongest for the metabolites of Di-isobutyl phthalate (DiBP), Di-isononyl phthalate (DiNP), and Di(2-ethylhexyl) phthalate (DEHP). Associations with metabolites of phthalate replacements tended to be in the same direction but weaker. Few sex differences were observed. Gestational phthalate exposure may be associated with alterations in placental chorionic plate surface vasculature characterized by more branching and shorter segments. These alterations may have implications for placental perfusion and suggest a placental mechanism by which phthalates may impact fetal development.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090374 | PMC |
http://dx.doi.org/10.1016/j.scitotenv.2024.178116 | DOI Listing |
BMC Pregnancy Childbirth
September 2025
Department of Gynecology & Obstetrics, Liaocheng People's Hospital, Dongchang Street 67, Liaocheng, China.
Background: Subamniotic hemorrhage, a rare condition involving bleeding between the amniotic membrane and fetal chorionic plate, presents diagnostic challenges.
Case Presentation: A 35-year-old woman at 37 weeks of gestation who presented with lower abdominal discomfort and decreased fetal movements came to our emergency department. Ultrasound revealed medium-strong echoes in the amniotic fluid and inhomogeneous echoes around the umbilical cord.
Arch Dis Child Fetal Neonatal Ed
August 2025
UMR 1153, CRESS, Obstetric, Perinatal, and Pediatric Life course Epidemiology, OPPaLE Team, INSERM, Paris, France.
Objective: To assess the association between histological chorioamnionitis without maternal clinical symptoms and neurodevelopmental disabilities at age 5 years in children born very preterm.
Design: French national prospective population-based cohort study, EPIPAGE-2 ().
Setting: All births from 22 to 34 weeks of gestational age in France in 2011 were eligible.
Placenta
August 2025
La Paz University Hospital, Pathology Department, Madrid, Spain.
Introduction: Breus' mole, or massive subchorionic thrombohematoma (MST), is an exceedingly rare placental condition associated with adverse pregnancy outcomes. We aim to describe the clinical, ultrasonographic, and histopathological features of newly diagnosed MST cases and review those previously reported.
Materials And Methods: We conducted a retrospective observational study of MST cases diagnosed between 2016 and 2024 in two Spanish referral hospitals for high-risk pregnancies.
Hum Reprod
September 2025
Global Research and Medical, Ferring Pharmaceuticals, Kastrup, Denmark.
Study Question: How do ovarian responses using conventional dosing for follitropin delta 15 µg/day compare with follitropin alfa 225 IU/day in women undergoing ovarian stimulation?
Summary Answer: The ADAPT-1 trial demonstrates similar ovarian responses with follitropin delta 15 µg/day and follitropin alfa 225 IU/day starting doses in a conventional dosing regimen.
What Is Known Already: Follitropin delta, a recombinant FSH (rFSH), is currently approved for ovarian stimulation using an individualized fixed daily dose based on serum anti-Müllerian hormone (AMH) and bodyweight (maximum 12 µg/day for first cycle and 24 µg/day in subsequent cycles). Other rFSHs, such as follitropin alfa, conventionally apply a starting dose of 150-225 IU, fixed for the initial days of stimulation, after which dose adjustments can be made (maximum 450 IU/day).
Front Physiol
June 2025
Maternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Introduction: This study aimed to investigate the acute effects of statins on maternal and fetoplacental vascular reactivity in vessels from pregnancies affected by pre-eclampsia (PE), a leading cause of maternal and fetal morbidity and mortality. Statins have been proposed as a candidate therapy due to their pleiotropic effects but evidence of statins' ability to ameliorate the observed endothelial dysfunction in PE is lacking.
Methods: Human chorionic plate arteries (CPAs) and omental arteries (OAs) from normal and PE pregnancies were mounted on a wire myograph.